BSE filing, NSE: ELITECON. Summary written from the filing by ALFA Finder's alert engine.
Elitecon International Ltd: key numbers
- Share price
- ₹6.84
- Market cap
- ₹1,093 Cr
- Revenue (annual)
- ₹5,075 Cr
- Net profit (annual)
- ₹162.0 Cr
- P/E (TTM)
- 5.7×Sector 36.4×
- Promoter holding
- 59.43%+0.00% QoQ
- FII holding
- 30.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Elitecon International Ltd
All →Elitecon International Annual General Meeting
Elitecon International Limited announced the voting results of its Postal Ballot, confirming the passage of seven resolutions including various director appointments.
Elitecon International Fund Raise of ₹1,000 Cr
Elitecon International's Board approved raising up to ₹1,000 Crore through a Qualified Institutions Placement (QIP) to eligible institutional buyers.
- Value
- ₹1,000 Cr
Elitecon International Board Meeting Date
Elitecon International has scheduled a board meeting on October 12, 2026, to consider raising capital through equity and debt instruments. No specific amount or mode is finalized.
Elitecon International Bags ₹574.2 Cr Order from World Class 77, South Africa
Elitecon International Limited has entered into a framework agreement with World Class 77, South Africa. The contract covers potential export supplies valued at approximately ₹574.20 Crore.
- Value
- ₹574.2 Cr
- From
- World Class 77, South Africa
- Execution
- Effective until August 31, 2027
Elitecon International Management Change
Elitecon International Limited has appointed M/s. Geeta & Co as its new Internal Auditor, replacing the outgoing firm Jain & Rajeev Associates.
Elitecon International Capital Structure Change
EBISU Global Opportunities Fund Limited has reduced its stake in Elitecon International Limited through open market sales between July 2026 and September 2026.
- Execution
- July 10, 2026, to September 18, 2026
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.